Samsung Bioepis’s Biosimilar Enbrel ‘Substitutable’ In Australia As Pfizer Patent Case Is Rebuffed
Executive Summary
Samsung Bioepis’s Brenzys has become the second biosimilar product to be reimbursed as substitutable at the pharmacy level in Australia, and a court has scotched Pfizer’s plans to initiate a patent infringement claim over the manufacturing process for the Enbrel/etanercept biosimilar.
You may also be interested in...
Australian ‘Uptake Drivers’ For Boosting Biosimilar Prescribing Start With Etanercept
Biosimilars are being given a boost in Australia through the use of “uptake drivers” to encourage doctors to prescribe a biosimilars in preference to the reference product. The first product involved is etanercept.
Australian ‘Uptake Drivers’ For Boosting Biosimilar Prescribing Start With Etanercept
Biosimilars are being given a boost in Australia through the use of “uptake drivers” to encourage doctors to prescribe a biosimilars in preference to the reference product. The first product involved is etanercept.
Australia's Biosimilar Substitution Policy Under Fire As Etanercept Product Is 'A'-Flagged
Australia's new policy of 'a'-flagging biosimilars, or allowing them to be substituted for the prescribed originator drug in the pharmacy, is coming under fire amid concerns that the move is overly driven by economic considerations and may not be the most appropriate way of improving patient access to cheaper biologic medicines.